METHOD FOR TREATING MIGRAINE HEADACHES

• US 20180243339A1
• Filed: 02/27/2018
• Published: 08/30/2018
• Est. Priority Date: 02/27/2017
• Status: Active Grant

• Current Assignee: Payman Sadeghi
• Original Assignee: Payman Sadeghi
• Inventors: Sadeghi, Payman
• Granted Patent: US 10,456,419 B2
• Time in Patent Office: Days
• CPC Class Codes: A61B 17/3421 Cannulas
• CPC Class Codes: A61B 17/3472 for bones, e.g. intraosseus injections
• CPC Class Codes: A61B 5/4076 Diagnosing or monitoring particular conditions of the nervous system A61B5/4821, A61B5/4824 take precedence
• CPC Class Codes: A61K 35/16 Blood plasma; Blood serum umbilical cord blood A61K35/51
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: C12N 5/0667 Adipose-derived stem cells [ADSC]; Adipose stromal stem cells

Abstract

A method for preventing and treating a headache in a patient is disclosed. The method includes locating one or more ligaments or muscle insertions that are associated with a cervical spine and a skull of the patient. The method further includes injecting into the determined one or more ligaments or muscle insertions an injectable regenerative solution that is derived from the patient to repair the one or more ligaments or muscle insertions. The method may further include determining a locus of the headache in the patient, determining one or more nerves associated with the locus of the headache, determining a set of the one or more ligaments or muscle insertions that are associated with the one or more nerves, and injecting the injectable regenerative solution into the determined set of the one or more ligaments or muscle insertions.

Claims

1. A method for preventing and treating a headache in a patient, comprising:

locating one or more ligaments or muscle insertions that are associated with a cervical spine and a skull of the patient; and

injecting into the determined one or more ligaments or muscle insertions an injectable regenerative solution that is derived from the patient to repair the one or more ligaments or muscle insertions.

2. The method of claim 1, further comprising:

determining a locus of the headache in the patient;

determining one or more nerves associated with the locus of the headache;

determining a set of the one or more ligaments or muscle insertions that are associated with the one or more nerves; and

injecting the injectable regenerative solution into the determined set of the one or more ligaments or muscle insertions.

3. The method of claim 2, wherein the nerves associated with the locus of the headache travel through the associated ligaments or muscle insertions.

4. The method of claim 1, further comprising preparing the injectable therapeutic solution.

5. The method of claim 4, wherein the injectable regenerative solution is an adipocyte-based stem cell concentrate, and preparing the injectable regenerative solution comprises:

aspirating fat from the patient to obtain fat aspirate;

centrifuging the fat aspirate, thereby separating concentrated adipose tissue out of the fat aspirate;

extracting the concentrated adipose tissue from the centrifuged fat aspirate; and

mixing the concentrated adipose tissue with concentrated platelet rich plasma (PRP).

6. The method of claim 5, further comprising:

prior to centrifuging, agitating the fat aspirate by pushing it back and forth through a 3-way stopcock; and

after centrifuging, agitating the concentrated adipose tissue by pushing it back and forth through an emulsifier.

7. The method of claim 5, further comprising:

aspirating 60 cc of fat;

centrifuging the fat aspirate for 3.5 minutes at 1500 RPM; and

mixing 23 cc of the concentrated adipose tissue with 7 cc of the concentrated PRP.

8. The method of claim 5, further comprising preparing the concentrated PRP by:

aspirating venous blood from the patient;

centrifuging the blood to separate plasma that includes a platelet suspension from red blood cells;

removing the plasma and platelet suspension from the centrifuged blood;

centrifuging the plasma and platelet suspension to concentrate platelets within the plasma, thereby separating platelet rich plasma from platelet poor plasma; and

removing the platelet poor plasma from the centrifuged plasma and platelet suspension until 7 cc of plasma remains.

9. The method of claim 8, further comprising agitating the remaining 7 cc of centrifuged plasma and platelet suspension.

10. The method of claim 4, wherein the injectable regenerative solution is a platelet rich plasma (PRP), and preparing the injectable regenerative solution comprises:

aspirating venous blood from the patient;

centrifuging the blood to separate plasma that includes a platelet suspension from red blood cells;

removing the plasma and platelet suspension from the centrifuged blood;

centrifuging the plasma and platelet suspension to concentrate platelets within the plasma, thereby separating platelet rich plasma from platelet poor plasma; and

removing the platelet poor plasma from the centrifuged plasma and platelet suspension.

11. The method of claim 10, further comprising:

aspirating 60 cc of venous blood using a syringe containing 10 cc of sodium citrate anticoagulant;

centrifuging the blood for 1.6 minutes at 3800 RPM;

centrifuging the plasma and platelet suspension for 4 minutes at 3800 RPM;

removing the platelet poor plasma until 10-15 mL of centrifuged plasma and platelet suspension remains; and

agitating the remaining 10-15 mL of centrifuged plasma and platelet suspension.

12. The method of claim 4, wherein the injectable regenerative solution is a bone-marrow-based stem cell concentrate, and preparing the injectable regenerative solution comprises:

aspirating bone marrow from a bone of the patient to obtain bone marrow aspirate;

centrifuging the bone marrow aspirate, thereby separating plasma from bone marrow cells;

removing the plasma from the centrifuged bone marrow aspirate;

removing a portion of the bone marrow cells from the centrifuged bone marrow aspirate;

adding the plasma to the portion of the bone marrow cells to create a bone marrow cell solution;

centrifuging the bone marrow cell solution, thereby separating bone marrow cells from the plasma;

removing a portion of the plasma to create a bone marrow concentrate; and

mixing the bone marrow concentrate with concentrated platelet rich plasma (PRP).

13. The method of claim 12, further comprising, before centrifuging, filtering the bone marrow aspirate to remove bone particles.

14. The method of claim 12, further comprising:

aspirating 60 cc of bone marrow using a syringe that contains heparin anticoagulant;

centrifuging the bone marrow aspirate for 2.5 minutes at 3800 RPM;

removing 2 cc of the bone marrow cells from the centrifuged bone marrow aspirate;

centrifuging the bone marrow cell solution for 8 minutes at 3800 RPM;

removing the plasma until 23 cc of bone marrow concentrate remains;

agitating the 23 cc of bone marrow concentrate; and

mixing the 23 cc of bone marrow concentrate with 7 cc of the concentrated PRP.

15. The method of claim 12, further comprising preparing the concentrated PRP by:

aspirating venous blood from the patient;

centrifuging the blood to separate plasma and platelet suspension from red blood cells;

removing the plasma and platelet suspension from the centrifuged blood;

centrifuging the plasma and platelet suspension to concentrate platelets within the plasma, thereby separating platelet rich plasma from platelet poor plasma; and

removing the platelet poor plasma from the centrifuged plasma and platelet suspension until 7 cc of plasma remains.

16. The method of claim 15, further comprising agitating the remaining 7 cc of centrifuged plasma and platelet suspension.

17. The method of claim 1, further comprising:

mixing Ropivacaine 0.2% with the injectable regenerative solution before injecting the injectable regenerative solution.

18. The method of claim 1, wherein the one or more ligaments or muscle insertions comprise a majority of ligaments or muscle insertions in the cervical spine and skull of the patient.

19. The method of claim 1, wherein the one or more ligaments or muscle insertions are associated with at least one of superior or inferior occipital ridges, a mastoid process, a spinous process of vertebrae C2 to C7, laminae and facet joints of vertebrae C2 to C7, a transverse process of vertebrae C1 to C5, or first and second ribs.

20. The method of claim 1, wherein 0.2-0.4 cc of the injectable regenerative solution is injected.